20(S)-protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide

被引:71
作者
Oh, GS
Pae, HO
Choi, BM
Seo, EA
Kim, DH
Shin, MK
Kim, JD
Kim, JB
Chung, HT [1 ]
机构
[1] Wonkwang Univ, Sch Med, Dept Microbiol & Immunol, Iksan 570749, Chonbuk, South Korea
[2] Wonkwang Univ, Med Resources Res Ctr, Iksan 570749, Chonbuk, South Korea
[3] Wonkwang Univ, Sch Med, Dept Ophthalmol, Iksan 570749, Chonbuk, South Korea
[4] Wonkwang Pharmaceut Co Ltd, Iksan, Chonbuk, South Korea
关键词
Panax ginseng; ginsenoside; 20(S)-protopanaxatriol; inducible nitric oxide synthase; cyclooxygenase-2; nuclear factor-kappa B; inflammation; chemoprevention;
D O I
10.1016/j.canlet.2003.09.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ginsenosides from Panax ginseng are metabolized by human intestinal bacteria after oral administration of ginseng extract. 20(S)-Protopanaxatriol (PPT) is one of the major metabolites of ginsenosides. Inducible nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) are important enzymes that mediate inflammatory processes. Improper up-regulation of iNOS and/or COX-2 has been associated with the pathogenesis of inflammatory diseases and certain types of human cancers. Here, we investigated whether PPT could modulate NOS and COX-2 expressions in RAW 264.7 macrophages stimulated with the endotoxin lipopolysaccharide (LPS). We found that PPT blocked the increase in LPS-induced iNOS and COX-2 expressions through inactivation of nuclear factor-kappaB by preventing I-kappaBalpha phosphorylation and degradation. Thus, it may be possible to develop PPT as a useful agent for chemoprevention of cancer or inflammatory diseases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 31 条
[1]   Ginseng pharmacology - Multiple constituents and multiple actions [J].
Attele, AS ;
Wu, JA ;
Yuan, CS .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1685-1693
[2]   Nuclear factor-kappa B and cancer: its role in prevention and therapy [J].
Bharti, AC ;
Aggarwal, BB .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :883-888
[3]  
Bing RJ, 2001, CLIN CANCER RES, V7, P3385
[4]   Transcription factors as targets for cancer therapy [J].
Darnell, JE .
NATURE REVIEWS CANCER, 2002, 2 (10) :740-749
[5]   The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line [J].
Fantappiè, O ;
Masini, E ;
Sardi, I ;
Raimondi, L ;
Bani, D ;
Solazzo, M ;
Vannacci, A ;
Mazzanti, R .
HEPATOLOGY, 2002, 35 (04) :843-852
[6]   Inflammation and the development of pancreatic cancer [J].
Farrow, B ;
Evers, BM .
SURGICAL ONCOLOGY-OXFORD, 2002, 10 (04) :153-169
[7]   Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas [J].
Gallo, O ;
Fabbroni, V ;
Sardi, I ;
Magnelli, L ;
Boddi, V ;
Franchi, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) :517-524
[8]   Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer [J].
Gilmore, T ;
Gapuzan, ME ;
Kalaitzidis, D ;
Starczynowski, D .
CANCER LETTERS, 2002, 181 (01) :1-9
[9]   Main Ginseng saponin metabolites formed by intestinal bacteria [J].
Hasegawa, H ;
Sung, JH ;
Matsumiya, S ;
Uchiyama, M .
PLANTA MEDICA, 1996, 62 (05) :453-457
[10]   Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol [J].
Hasegawa, H ;
Suzuki, R ;
Nagaoka, T ;
Tezuka, Y ;
Kadota, S ;
Saiki, I .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (07) :861-866